Less than a month after winning its first FDA authorization, 23andMe is expanding beyond direct-to-consumer genetic testing by creating a new therapeutics group, and appointing Genentech’s recently retired evp of research and early development to lead the new unit. Richard Scheller, Ph.D., has been named 23andMe’s CSO and head of…

In oncology, more precise treatments for many different forms of cancer are in the offing, a prospect that makes oncologists the envy of other healthcare professionals. Already, cancer companion diagnostics can show doctors the specific drug that will be most effective in treating a particular subtype of cancer. Unfortunately, such…